Literature DB >> 24139279

Heterozygous TREM2 mutations in frontotemporal dementia.

Barbara Borroni1, Francesca Ferrari2, Daniela Galimberti3, Benedetta Nacmias4, Cinzia Barone3, Silvia Bagnoli4, Chiara Fenoglio3, Irene Piaceri4, Silvana Archetti5, Cristian Bonvicini6, Massimo Gennarelli6, Marinella Turla7, Elio Scarpini3, Sandro Sorbi4, Alessandro Padovani2.   

Abstract

A causative association was recently demonstrated between homozygous TREM2 mutations and frontotemporal dementia (FTD)-like syndrome and between heterozygous TREM2 exon2 genetic variations and late-onset Alzheimer's disease (AD). The objective of this study was to evaluate whether heterozygous TREM2 genetic variations might be associated to the risk of FTD. TREM2 exon 2 was sequenced in a group of 1030 subjects-namely, 352 patients fulfilling clinical criteria for FTD, 484 healthy control subjects (HCs), and 194 patients with AD. The mutation frequency and the associated clinical characteristics were analyzed. We identified 8 missense and nonsense mutations in TREM2 exon 2 in 24 subjects. These mutations were more frequent in patients with FTD than in HCs (4.0% vs. 1.0%, p = 0.005). In particular, TREM2 Q33X, R47H, T66M, and S116C mutations were found in FTD and were absent in HCs. These mutations were associated with either the semantic variant of primary progressive aphasia or the behavioral variant FTD phenotypes. The FTD and AD groups were not significantly different with regard to TREM2 genetic variation frequency (AD: 2.6%, p = 0.39). Heterozygous TREM2 mutations modulate the risk of FTD in addition to increasing susceptibility to AD. Additional studies are warranted to investigate the possible role of these mutations in the pathogenesis of neurodegenerative disorders.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Frontotemporal dementia; Frontotemporal lobar degeneration; Mutation; Risk factor; TREM2

Mesh:

Substances:

Year:  2013        PMID: 24139279     DOI: 10.1016/j.neurobiolaging.2013.09.017

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  66 in total

1.  The anti-inflammatory glycoprotein, CD200, restores neurogenesis and enhances amyloid phagocytosis in a mouse model of Alzheimer's disease.

Authors:  Megan M Varnum; Tomomi Kiyota; Kaitlin L Ingraham; Seiko Ikezu; Tsuneya Ikezu
Journal:  Neurobiol Aging       Date:  2015-08-01       Impact factor: 4.673

Review 2.  TREM2 variants: new keys to decipher Alzheimer disease pathogenesis.

Authors:  Marco Colonna; Yaming Wang
Journal:  Nat Rev Neurosci       Date:  2016-02-25       Impact factor: 34.870

Review 3.  Triggering receptor expressed on myeloid cells 2 (TREM2): a potential therapeutic target for Alzheimer disease?

Authors:  Yuetiva Deming; Zeran Li; Bruno A Benitez; Carlos Cruchaga
Journal:  Expert Opin Ther Targets       Date:  2018-06-20       Impact factor: 6.902

4.  TREM2 variants and risk of Alzheimer's disease: a meta-analysis.

Authors:  Yanjun Lu; Wei Liu; Xiong Wang
Journal:  Neurol Sci       Date:  2015-06-03       Impact factor: 3.307

5.  TREM2 regulates microglial cell activation in response to demyelination in vivo.

Authors:  Claudia Cantoni; Bryan Bollman; Danilo Licastro; Mingqiang Xie; Robert Mikesell; Robert Schmidt; Carla M Yuede; Daniela Galimberti; Gunilla Olivecrona; Robyn S Klein; Anne H Cross; Karel Otero; Laura Piccio
Journal:  Acta Neuropathol       Date:  2015-01-29       Impact factor: 17.088

6.  Preparation, crystallization, and preliminary crystallographic analysis of wild-type and mutant human TREM-2 ectodomains linked to neurodegenerative and inflammatory diseases.

Authors:  Daniel L Kober; Kelsey M Wanhainen; Britney M Johnson; David T Randolph; Michael J Holtzman; Tom J Brett
Journal:  Protein Expr Purif       Date:  2014-02-07       Impact factor: 1.650

7.  The triggering receptor expressed on myeloid cells 2 (TREM2) is associated with enhanced inflammation, neuropathological lesions and increased risk for Alzheimer's dementia.

Authors:  Panos Roussos; Pavel Katsel; Peter Fam; Weilun Tan; Dushyant P Purohit; Vahram Haroutunian
Journal:  Alzheimers Dement       Date:  2014-12-09       Impact factor: 21.566

Review 8.  TREM2-Ligand Interactions in Health and Disease.

Authors:  Daniel L Kober; Tom J Brett
Journal:  J Mol Biol       Date:  2017-04-19       Impact factor: 5.469

9.  CSF soluble TREM2 as a measure of immune response along the Alzheimer's disease continuum.

Authors:  Boris-Stephan Rauchmann; Thomas Schneider-Axmann; Panagiotis Alexopoulos; Robert Perneczky
Journal:  Neurobiol Aging       Date:  2018-10-25       Impact factor: 4.673

Review 10.  The role of CHMP2BIntron5 in autophagy and frontotemporal dementia.

Authors:  Christopher S Krasniak; S Tariq Ahmad
Journal:  Brain Res       Date:  2016-03-10       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.